580 completed. 580 Phase 1, 121 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 580 | Completed 580 |
| Phase 2 | 121 | Completed 121 |
Follow Neoplasm Metastasis: new trials by email Literature Review of Neoplasm Metastasis trials Research Report on Neoplasm Metastasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Material Balance of [14C]Zorifertinib in Healthy Adult Male Participants in China [14C]Zorifertinib Oral Formulation - EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases | Phase 1 | Completed | Alpha Biopharma (Jiangsu) Co., Ltd. | 6 | 2026-07-06 | 2026-09-22 |
| A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer Behavioral Intervention, Group Therapy, Psilocybin - Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Completed | University of Washington | 15 | 2024-11-19 | 2025-10-14 |
| A Clinical Trial to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects VC004 and Itraconazole, VC004 and rifampicin - Locally Advanced or Metastatic Solid Tumor | Phase 1 | Completed | Jiangsu vcare pharmaceutical technology co., LTD | 56 | 2024-09-18 | 2024-12-10 |
| Phase I Trial of Combined Immune Cell Therapy for Metastatic Stage IV Solid Tumors (SDH-Combi) Combi - Solid Tumors, Metastatic | Phase 1 | Completed | Seoul Hospital | 9 | 2024-08-01 | 2025-10-01 |
| A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001) MK-6837, Pembrolizumab, Rescue Medications - Neoplasm Metastasis | Phase 1 | Completed | Merck Sharp & Dohme LLC | 40 | 2024-07-14 | 2026-08-28 |
| BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors BGB-43395, Fulvestrant, Letrozole - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Completed | BeOne Medicines | 33 | 2024-04-01 | 2026-06-10 |
| Clinical Study of SM3321 With Solid Tumors SM3321 - Locally Advanced or Metastatic Solid Tumors | Phase 1 | Completed | Beijing StarMab Biomed Technology Ltd | 7 | 2023-12-07 | 2026-07-23 |
| Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C Mutation BEBT-607Tablets - Advanced or Metastatic Solid Tumor, KRAS G12C Mutation | Phase 1 | Completed | BeBetter Med Inc | 11 | 2023-09-18 | 2026-08-18 |
| Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy SNK02 - Pathologically Confirmed Cancer Refractory to Conventional Therapy, Refractory Cancer | Phase 1 | Completed | NKGen Biotech, Inc. | 6 | 2023-08-23 | 2024-11-20 |
| Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer Counseling, Psilocybin, Questionnaire Administration - Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 / Phase 2 | Completed | University of Washington | 55 | 2023-06-27 | 2025-11-05 |
| To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies Tisotumab Vedotin - Solid Malignancies | Phase 1 | Completed | Zai Lab (Shanghai) Co., Ltd. | 19 | 2023-06-16 | 2023-11-27 |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | Sensei Biotherapeutics, Inc. | 98 | 2023-05-31 | 2026-09-02 |
| PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation PRT3789, Docetaxel - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Completed | Prelude Therapeutics Incorporated | 135 | 2023-05-02 | 2025-10-16 |
| Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer VIP236 (Q3W), VIP236 (Q2W) - Neoplasms | Phase 1 | Completed | Vincerx Pharma, Inc. | 29 | 2023-01-24 | 2024-11-15 |
| Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer IGM-7354 - Solid Tumor | Phase 1 | Completed | IGM Biosciences, Inc. | 14 | 2023-01-10 | 2024-07-24 |
| A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). ANV419 - Melanoma (Skin), Cutaneous Melanoma | Phase 1 / Phase 2 | Completed | Anaveon AG | 29 | 2022-12-16 | 2025-08-26 |
| Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors GEN1056 - Solid Tumor, Adult | Phase 1 | Completed | Genmab | 26 | 2022-10-24 | 2025-11-24 |
| A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer IOA-289 - Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Completed | iOnctura | 16 | 2022-10-10 | 2026-03-30 |
| Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy Atezolizumab, 6-mercaptopurine, 6-thioguanine - Solid Tumor, Adult, Metastatic Cancer | Phase 1 / Phase 2 | Completed | Kristoffer Rohrberg | 18 | 2022-09-01 | 2026-01-14 |
| Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors WTX-124, pembrolizumab - Metastatic Solid Tumor, Advanced Solid Tumor | Phase 1 | Completed | Werewolf Therapeutics, Inc. | 156 | 2022-08-15 | 2026-10-09 |
Showing 20 of 580. Sign in to see all of them.
Neoplasms (168) · Breast Neoplasms (89) · Carcinoma, Non-Small-Cell Lung (69) · Colorectal Neoplasms (66) · Melanoma (66) · Pancreatic Neoplasms (52) · Recurrence (38) · Ovarian Neoplasms (37) · Prostatic Neoplasms (37) · Lung Neoplasms (36) · Stomach Neoplasms (34) · Colonic Neoplasms (30) · Head and Neck Neoplasms (30) · Carcinoma, Renal Cell (28)
Pathological Conditions, Signs and Symptoms (580) · Neoplastic Processes (577) · Pathologic Processes (577) · Neoplasms (412) · Neoplasms by Site (347) · Neoplasms by Histologic Type (194) · Skin and Connective Tissue Diseases (149) · Skin Diseases (148) · Digestive System Diseases (141) · Digestive System Neoplasms (137) · Neoplasms, Glandular and Epithelial (127) · Urogenital Diseases (108) · Urogenital Neoplasms (104) · Gastrointestinal Diseases (101) · Breast Diseases (100)
Gemcitabine (32) · Paclitaxel (27) · Nivolumab (24) · pembrolizumab (22) · Capecitabine (20) · Cisplatin (20) · Fluorouracil (19) · Bevacizumab (18) · Docetaxel (15) · Leucovorin (15) · Oxaliplatin (15) · Trastuzumab (15) · Irinotecan (13) · Carboplatin (12) · Everolimus (12)
Eli Lilly and Company (35) · National Cancer Institute (NCI) (35) · M.D. Anderson Cancer Center (27) · AstraZeneca (16) · Memorial Sloan Kettering Cancer Center (16) · H. Lee Moffitt Cancer Center and Research Institute (11) · Amgen (7) · Duke University (7) · Merck Sharp & Dohme LLC (7) · Novartis Pharmaceuticals (7) · Pfizer (7) · Bayer (6) · OncoMed Pharmaceuticals, Inc. (6) · Akamis Bio (5) · Altor BioScience (5)
United States (441) · Spain (59) · United Kingdom (43) · France (42) · Canada (40) · Japan (31) · Belgium (30) · Australia (28) · Germany (26) · Italy (26) · Netherlands (23) · South Korea (18) · China (17) · Taiwan (11) · Switzerland (9)
Brendan Curti, MD (4) · Darell D. Bigner, MD, PhD (4) · David S. Schrump, MD (3) · Jana Portnow, MD (3)
PMID 36897458, PMID 24919854, PMID 25100135, PMID 39462179, PMID 10553041, PMID 12082455, PMID 12082456, PMID 12393999, PMID 15338206, PMID 15944250, PMID 16009951, PMID 16533779, PMID 17985341, PMID 17987262, PMID 19060590, PMID 19192962, PMID 19233901, PMID 19372041, PMID 19602035, PMID 19735988, PMID 20407240, PMID 20595147, PMID 21034418, PMID 21107682, PMID 21367608, PMID 21730275, PMID 21784628, PMID 21850464, PMID 21994418, PMID 22067397, PMID 22210018, PMID 22248721, PMID 22491798, PMID 22872523, PMID 22878520, PMID 23179335, PMID 23197081, PMID 23211938, PMID 23255417, PMID 23345000, PMID 23530663, PMID 23535954, PMID 23547075, PMID 23653243, PMID 23724846, PMID 23756764, PMID 24013904, PMID 24063698, PMID 24362862, PMID 24567516
2015 (7), P30CA016672 (6), 2017 (5), 2014 (4), 2016 (4), UM1CA186709 (4), 2008 (3), 2018 (3), P30CA033572 (3), UM1CA186689 (3), 2009 (2), 2023 (2), P30CA012197 (2), P30CA016087 (2), U01CA062487 (2)